Genocea Announces Poster Presentation at The European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference
Additional positive GEN-009 clinical immunogenicity data driven by ATLAS™ to be presented at
Company to present at the Cantor Fitzgerald 2019 Global
In the new interim GEN-009 clinical update, immune response data will be presented from a subset of seven patients in the 50-day primary immunogenicity readout, including data from two additional patients from last reported. For the patients (n=5) with both preliminary ex vivo and IVS data, GEN-009 generated immune responses to 98 percent of all immunized peptides, which is unprecedented for neoantigen vaccination administered without checkpoint inhibition. The study is currently accruing for Part B to evaluate GEN-009 in combination with standard-of care immunotherapy regimens, with preliminary data expected in mid-2020.
“With these data presented at
Poster presentation details:
- Title: A phase 1 trial of GEN-009, a neoantigen vaccine using ATLAS, an autologous immune assay, to identify immunogenic and inhibitory tumor mutations.
- Abstract # 2234, Poster # 1178PD (Hall 3)
- Presenter: Dr.
Inge Marie Svane, Copenhagen University
Saturday, September 28, 2019from 4:30 - 4:50 p.m. CEST
Bilbao Auditorium, Fira Gran Via, Barcelona, Spain
Cantor Fitzgerald 2019 Global Healthcare Conference details:
Thursday, October 3, 2019
1:50 p.m. ET
New York, NY
A live webcast of the Cantor Fitzgerald presentation can be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at http://ir.genocea.com. Replays of the webcasts will be archived for 90 days following the conferences.
Genocea is a biopharmaceutical company developing personalized cancer immunotherapies. Our unique ATLAS™ technology platform allows us to identify targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, we can both optimize neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that exert an immunosuppressive effect on anti-tumor immune responses. We are advancing complementary programs built from ATLAS insights: GEN-009, our neoantigen vaccine candidate for which we are conducting a Phase 1/2a clinical trial across a variety of solid tumor types, and GEN-011, our neoantigen-specific adoptive T cell therapy, for which we intend to file an Investigational New Drug Application in the first half of 2020. To learn more, please visit www.genocea.com.
Forward Looking Statements
This press release includes forward-looking statements, including statements relating to GEN-009 and GEN-011, within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended
Source: Genocea Biosciences, Inc.